29th Sep 2021 08:30
(Alliance News) - Brentford,England-based pharmaceutical company GlaxoSmithKline PLC on Wednesday said ViiV Healthcare reported three-year results from the Tango study of HIV.
ViiV is a HIV company majority owned by GSK, with Pfizer Inc and Shionogi Ltd as shareholders.
GSK said findings showed that the 2-drug regimen dovato continued to demonstrate non-inferior efficacy and a high barrier to resistance compared to continuation of tenofovir alafenamide fumarate-based regimens of at least three drugs. The study was conducted in virologically suppressed adults living with HIV-1 who had not experienced prior virologic failure.
At three years, no participants on dovato met confirmed protocol-defined virologic failure, versus three participants on the tenofovir alafenamide fumarate-based regimen. No resistance mutations were reported in either trial.
"As we now consider HIV a long-term condition requiring life-long medication, these results give physicians the data they need to have more confidence in switching their virologically suppressed patients who are taking three or more medicines," said Olayemi Osiyemi, lead author and one of the investigators of the Tango study.
FTSE 100-listed GSK shares were trading 0.8% higher in London on Wednesday at 1,394.20 pence each.
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline